Pangu BioPharma is a subsidiary of aTyr Pharma in Hong Kong. Pangu supports basic and translational research in tRNA synthetase biology in collaboration with the Hong Kong University of Science and Technology (HKUST). Researchers, including experts in molecular biology, genetics and protein structure, have identified many naturally occurring splice variants of human amino-acyl tRNA synthetases and characterized their extracellular signaling functions. The Hong Kong government, through its Innovation and Technology Commission (ITC), has provided financial support for this collaborative work.
About aTyr Pharma
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. For more information, please visit www.atyrpharma.com
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestone For First Year of Government Grant to Develop Bispecific Antibody Platform
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform